Class of 1970 Commemorative Biographical Book

I V O R R O Y S T O N Address: 7514 Girard Ave, Suite 1 PMB 243, La Jolla, CA 92037 Email: iroyston@viracta.com ● Phone: H: 858-454-4694 ● C: 858-449-1136

Alma mater: Johns Hopkins University 1967

Postgraduate Training/Certification: Post-doctoral training in internal medicine & medical oncology at Stanford University Professional and Volunteer Awards and Recognition: San Diego Entrepreneur of the Year Award Appointed by President Clinton to a six-year term on the National Cancer Advisory Board Inducted into the San Diego Entrepreneur Hall of Fame The 2019 Xconomy Lifetime Achievement Award The 2020 Biotechnology Heritage Award from BIO and the Science History Institute Name(s) of Children and Grandchildren: Children: Aaron Royston, Natalie Royston Scoma Grandchildren: Aya Royston, Zach Scoma, and Chase Scoma Narrative: What was your most memorable moment from medical school? Being in the company of some of the giants of medicine in the 60’s. e.g.: Tumulty, Harvey, Wood, McKusick, Mountcastle, Lehninger What highlights have you experienced since graduating in 1970? Attending Stanford for post-graduate training and fellowship and being one of the first to use the Kohler-Milstein technology for making monoclonal antibodies, now the most important class of biologics in oncology. One of my most exciting highlights since graduating was co-founding Hybritech, Inc., San Diego’s first biotechnology company, in 1978, where we developed the PSA test for prostate cancer. The group of scientists and executives involved with this venture would go on to create dozens of biotechnology companies in San Diego, helping to launch the region’s biotech industry, for which it is now globally recognized. I am very proud of this achievement. Current Employment: Viracta Therapeutics, Inc., President & CEO Spouse or Partner’s Name: Colette Carson Royston

Following Hybritech, Inc., I co-founded IDEC Corporation also in San Diego, which developed the first monoclonal antibody therapy for cancer (Rituxan). And now, I am in the bookend of my career, beginning where I started my initial scientific research and my medical training in viral diseases and oncology in the Department of Microbiology at Hopkins. And now, I am the President, CEO and director of Viracta Therapeutics, a San Diego-based biotechnology company focused on novel therapies for viral- associated cancers. This current role has brought my work since medical school truly full circle. How have you changed since medical school? I am still the same curious boy who came to Baltimore in 1965 to become a physician scientist to find a cure for cancer, and I am still looking.

59